# Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients

> **NCT03221842** · PHASE3 · TERMINATED · sponsor: **CSL Behring** · enrollment: 63 (actual)

## Conditions studied

- Antibody-mediated Rejection

## Interventions

- **DRUG:** C1-esterase inhibitor
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03221842
- **Lead sponsor:** CSL Behring
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-11-06
- **Primary completion:** 2021-01-20
- **Final completion:** 2021-01-20
- **Target enrollment:** 63 (ACTUAL)
- **Why stopped:** The study was terminated early due to futility of enrolment and not for safety reasons.
- **Last updated:** 2022-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03221842

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03221842, "Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03221842. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*